Immune persistence and safety of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial
AS01(E)佐剂呼吸道合胞病毒融合前F蛋白疫苗在50-59岁成人(包括高危成人)中的免疫持久性和安全性:一项随机对照试验
期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2025.2579335
Ferguson, Murdo; Schwarz, Tino F; Núñez, Sebastián A; Rodríguez-García, Juan; Mital, Marek; Zala, Carlos; Pek, Bonavuth; Schmitt, Bernhard; Toursarkissian, Nicole; Ochoa Mazarro, Dolores; Großkopf, Josef; Voors-Pette, Christine; Mehta, Hemalini; Amare Hailemariam, Hiwot; Gérard, Catherine; Damaso, Silvia; David, Marie-Pierre; Descamps, Dominique; Hill, Judith; Vandermeulen, Corinne; Hulstrøm, Veronica